Byrne Wallace Shields LLP‘s intellectual property team assists in a range of contentious and non-contentious IP mandates, including brand and design protection. Considered a go-to for clients in the life sciences sector, Colin Sainsbury leads the non-contentious IP offering and regularly drafts and negotiates licensing, supply and service agreements.
Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • ‘Personal attention to detail and responsiveness makes this team unique.’
  • 'Excellent to deal with good communication and easy to understand.'
  • 'Colin Sainsbury is a long standing and well renowned professional.'
  • ‘Jane O'Grady is clearly a subject matter expert in the Intellectual Property domain and all my questions were comprehensively answered. Jane also adopts a commercial pragmatic approach which is especially helpful.’
  • ‘Strong teamwork and culture. Good coordination amongst partners in terms of responding to client queries.’

Key clients

  • Starbucks Corporation
  • Headstuff Podcasts
  • Corpay
  • Suil Vision
  • UltraGreen.ai/Renew Pharma
  • Neuromod Devices Limited
  • Priothera Limited
  • Xeolas Pharmaceuticals Limited
  • Versono Medical Limited
  • Warburton Technology
  • European Circular Bioeconomy Fund
  • Q3 Medical Devices Limited

Work highlights

Advising MVM Partners (the lead investor) and OrbiMed in relation to the announced $80m Series B financing of ProVerum Limited
Advising StatisticaMedica on the negotiation and successful conclusion of a number of complex master services agreements with multinational life sciences companies.
Practice head

Colin Sainsbury

Other key lawyers

Victor Timon; Laura Greene